Cellectar Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. (CLRB) on November 15, 2024. The report addresses an administrative correction regarding the Company's amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023, which was originally filed on October 29, 2024.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is procedural and does not contain new financial performance data.
Material Changes
There are no material changes to previously reported financial results. The filing corrects an inadvertent omission in the consent of the independent registered public accounting firm dated October 29, 2024. The original consent failed to reference specific registration statements on Forms S-1, S-1 MEF, and S-3. A Revised Consent dated November 15, 2024, has been filed to rectify this omission.
Guidance, Outlook, and Risks
The filing contains no new management guidance, outlook, or discussion of risks and contingencies. The Company explicitly states that the Revised Consent does not change any previously reported financial results or other disclosure contained in the Form 10-K.
Key Facts for Investor Verification
- The filing is a corrective measure for an administrative error in the auditor's consent attached to the 2023 Form 10-K/A.
- The omission involved missing references to specific registration statements (File Nos. 333-208638, 333-214310, 333-225675, 333-231888, 333-238132, 333-268554, 333-226374, 333-238892, 333-208189, 333-252309, 333-274880, and 333-279731).
- No financial data or operational metrics were altered by this filing.
- Investors should verify the attached Exhibit 23.1 (Revised Consent) to confirm the inclusion of the previously omitted registration statement references.